


# **IN THE CLAIMS:**

This listing of Claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A compound having the structure (I):



(I)

or pharmaceutically acceptable derivative salt, ester or salt of such ester thereof;

wherein n is an integer from 0-4;

R<sub>1</sub> is hydrogen, -NH<sub>2</sub>, -NHMe, -NHAc, -OH, F, -OMe, -CN, or -NH(C=O)OEt;


R<sub>2</sub> is hydrogen, -NR<sub>A</sub>R<sub>B</sub>, -OR<sub>A</sub>, an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R<sub>A</sub> and R<sub>B</sub> are each independently hydrogen or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

each occurrence of R<sub>3</sub> is independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group -G-R<sub>C</sub>, wherein G is absent or is -CH<sub>2</sub>-, -NR<sub>D</sub>-, -O-, or (C=O), and wherein R<sub>C</sub> is hydrogen, -NR<sub>F</sub>R<sub>G</sub>, -OR<sub>F</sub>, -SR<sub>F</sub>, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R<sub>D</sub>, R<sub>F</sub> and R<sub>G</sub> are each independently hydrogen, -NR<sub>x</sub>R<sub>y</sub>, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R<sub>D</sub> and R<sub>C</sub> or R<sub>F</sub> and R<sub>G</sub> taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of R<sub>x</sub> and R<sub>y</sub> is independently hydrogen, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R<sub>x</sub> and R<sub>y</sub> taken together are a 4-, 5- or 6-membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be

independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.


2. (Original) The compound of claim 1, wherein the compound has the structure:



wherein R<sub>3a</sub> and R<sub>3b</sub> are each independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group -G-R<sub>C</sub>, wherein G is absent, -CH<sub>2</sub>-, -NR<sub>D</sub>-, -O-, or (C=O), and wherein R<sub>C</sub> is hydrogen, -NR<sub>F</sub>R<sub>G</sub>-, -OR<sub>F</sub>-, -SR<sub>F</sub>-, or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein R<sub>D</sub>, R<sub>F</sub> and R<sub>G</sub> are each independently hydrogen, -NR<sub>x</sub>R<sub>y</sub>-, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R<sub>D</sub> and R<sub>C</sub> or R<sub>F</sub> and R<sub>G</sub> taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of R<sub>x</sub> and R<sub>y</sub> is independently hydrogen, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein R<sub>x</sub> and R<sub>y</sub> taken together are a 4-, 5- or 6-membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.


3. (Original) The compound of claim 1, wherein the compound has the structure:



wherein  $R_{3a}$  and  $R_{3b}$  are each independently hydrogen, halogen, cyano, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or a group  $-G-R_C$ , wherein  $G$  is absent,  $-CH_2-$ ,  $-NR_D-$ ,  $-O-$ , or  $(C=O)$ , and wherein  $R_C$  is hydrogen,  $-NR_F R_G$ ,  $-OR_F$ ,  $-SR_F$ , or an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, wherein  $R_D$ ,  $R_F$  and  $R_G$  are each independently hydrogen,  $-NR_x R_y$ , an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein  $R_D$  and  $R_C$  or  $R_F$  and  $R_G$  taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted cycloaliphatic or cycloheteroaliphatic moiety; wherein each occurrence of  $R_x$  and  $R_y$  is independently hydrogen, an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety, an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety, or wherein  $R_x$  and  $R_y$  taken together are a 4-, 5- or 6-membered substituted or unsubstituted, saturated or unsaturated cycloaliphatic or cycloheteroaliphatic moiety;


whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

4. (Original) The compound of claim 1, wherein the compound has the structure:




wherein  $R_1$ ,  $R_2$ ,  $R_F$  and  $R_G$  are as defined in claim 1.

5. (Original) The compound of claim 1, wherein the compound has the structure:




wherein  $R_1$ ,  $R_2$ ,  $R_F$  and  $R_G$  are as defined in claim 1.

6. (Original) The compound of claim 1, wherein the compound has the structure:




wherein  $R_1$ ,  $R_2$ ,  $R_F$  and  $R_G$  are as defined in claim 1.

7. (Original) The compound of claim 1, wherein the compound has the structure:




wherein  $q$  and  $r$  are each independently 0 or 1; and  $R_1$ ,  $R_2$ ,  $R_F$  and  $R_G$  are as defined in claim 1.

8. (Original) The compound of claim 1, wherein the compound has the structure:




wherein  $q$  and  $r$  are each independently 0 or 1; and  $R_1$ ,  $R_2$ ,  $R_F$  and  $R_G$  are as defined in claim 1.

9. (Original) The compound of claim 1, wherein the compound has the structure:




wherein  $R_1$ ,  $R_2$ ,  $R_F$  and  $R_G$  are as defined in claim 1.

10. (Original) The compound of claim 1, wherein the compound has the structure:



wherein  $R_1$ ,  $R_2$ ,  $R_F$  and  $R_G$  are as defined in claim 1.

11. (Original) The compound of claim 1, wherein the compound has the structure:




wherein  $R_1$  and  $R_2$  are as defined in claim 1;

$m$  is 0, 1 or 2; and

$R^F$  is an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

12. (Original) The compound of claim 1, wherein the compound has the structure:




wherein  $R_1$  and  $R_2$  are as defined in claim 1; and

$R_F$  is hydrogen, a protective group or an aliphatic, cycloaliphatic, heteroaliphatic, cycloheteroaliphatic, aryl, or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated; and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

13. (Original) The compound of claim 1, wherein the compound has the structure:




wherein  $R_1$  and  $R_2$  are as defined in claim 1;

G is  $CH_2$  or  $-(C=O)$ ; and

X is O, S, C=O, S=O,  $C=CR_4R_5$ ,  $NR_4$ , or  $CR_4R_5$ ; wherein each occurrence of  $R_4$  and  $R_5$  is independently hydrogen, hydroxyl, halogen, cyano an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

14. (Original) The compound of claim 1, wherein the compound has the structure:




wherein  $R_1$  and  $R_2$  are as defined in claim 1;

$G$  is  $CH_2$  or  $-(C=O)$ ; and

$X$  is  $O$ ,  $S$ ,  $C=O$ ,  $S=O$ ,  $C=CR_4R_5$ ,  $NR_4$ , or  $CR_4R_5$ ; wherein each occurrence of  $R_4$  and  $R_5$  is independently hydrogen, hydroxyl, halogen, cyano an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

15. (Original) The compound of claim 1, wherein the compound has the structure:



wherein  $R_1$  and  $R_2$  are as defined in claim 1;


$G$  is  $CH_2$  or  $-(C=O)$ ; and

$X$  is  $O$ ,  $S$ ,  $C=O$ ,  $S=O$ ,  $C=CR_4R_5$ ,  $NR_4$ , or  $CR_4R_5$ ; wherein each occurrence of  $R_4$  and  $R_5$  is independently hydrogen, hydroxyl, halogen, cyano an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be

independently substituted or unsubstituted, cyclic or acyclic, linear or branched, and wherein each of the foregoing aryl or heteroaryl moieties may be independently substituted or unsubstituted.

16. (Original) The compound of claim 1, wherein the compound has the structure:



wherein  $R_1$  and  $R_2$  are as defined in claim 1;

$p$  is an integer from 0-3;

$s$  is an integer from 0-4;

A, B, D, E and each occurrence of K are independently absent, O, S,  $-C=O$ ,  $-S=O$ ,  $-C=CR_4R_5$ ,  $-NR_4$ , or  $-CR_4R_5$ , wherein each occurrence of  $R_4$  and  $R_5$  is independently hydrogen, hydroxyl, halogen, cyano,  $-OR_x$ ,  $-SR_x$ ,  $-NR_xR_y$ , an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, or is an acyl moiety substituted with an aliphatic, heteroaliphatic, aryl or heteroaryl moiety; and wherein A and B, B and D, D and E, E and K and any two adjacent K groups may be linked by a single or double bond as valency permits; wherein each occurrence of  $R_x$  and  $R_y$  is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl, heteroaryl, aliphaticaryl, heteroaliphatic aryl, aliphaticheteroaryl or heteroaliphaticheteroaryl moiety;

whereby each of the foregoing aliphatic or heteroaliphatic moieties may be independently substituted or unsubstituted, cyclic or acyclic, linear or branched, saturated or unsaturated and wherein each of the foregoing aryl, heteroaryl aliphaticaryl, heteroaliphatic aryl, aliphaticheteroaryl or heteroaliphaticheteroaryl moieties may be independently substituted or unsubstituted.

17. (Original) The compound of any one of claims 1-16, wherein  $R_1$  is  $NH_2$ .

18. (Original) The compound of any one of claims 1-16, wherein  $R_1$  is hydrogen.



19. (Original) The compound of any one of claims 1-16, wherein  $R_2$  is  $NH_2$ , OH,  $C_1-C_6$  alkyl or  $C_1-C_6$  alkenyl, said alkyl and alkenyl groups optionally substituted with halogen or hydroxyl.

20. (Original) The compound of any one of claims 1-16, wherein  $R_2$  is  $C_1-C_2$  alkyl.

21. (Original) The compound of any one of claims 1-16, wherein  $R_2$  is methyl.

22. (Original) The compound of any one of claims 1-16, wherein  $R_2$  is hydrogen.

23. (Original) The compound of any one of claims 4-10, wherein one of  $R_F$  or  $R_G$  is hydrogen or lower alkyl; and the other is an alkyl, heteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein  $R_F$  and  $R_G$  taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted, saturated or unsaturated cyclic or heterocyclic moiety.

24. (Original) The compound of any one of claims 4-10, wherein one of  $R_F$  or  $R_G$  is hydrogen or lower alkyl; and the other is an aryl, heteroaryl, alkylaryl or alkylheteroaryl moiety, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl, or wherein  $R_F$  and  $R_G$  taken together are a 3-, 4-, 5-, 6-, 7- or 8-membered substituted or unsubstituted, saturated or unsaturated cyclic or heterocyclic moiety.

25. (Original) The compound of claim 24, wherein one of  $R_F$  or  $R_G$  is hydrogen or lower alkyl; and the other is phenyl, pyridyl, (alkyl)phenyl, or (alkyl)pyridyl, optionally substituted with one or more occurrences of halogen, trifluoromethoxy, methoxy, trifluoromethyl, methylthio, or substituted or unsubstituted lower alkyl, lower heteroalkyl, aryl or heteroaryl.

26. (Original) The compound of any one of claims 4-10, wherein one of  $R_F$  or  $R_G$  is hydrogen or lower alkyl; and the other is a cyclic or acyclic, linear or branched, saturated or unsaturated aliphatic moiety optionally substituted with one or more of substituted or unsubstituted aryl, heteroaryl, amide, alkoxy, hydroxyl, thioalkyl, thiol, acyl or amino.

27. (Original) The compound of claim 11, wherein  $R_F$  is an alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl.

28. (Original) The compound of claim 12, wherein  $R_F$  is hydrogen, a protecting group, or an alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, optionally independently substituted for each occurrence with one or more of halogen, alkoxy, thioalkyl, or substituted or unsubstituted alkyl, heteroalkyl, aryl, or heteroaryl.

29. (Previously Presented) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent; and optionally further comprising an additional therapeutic agent.

30. (Previously Presented) The pharmaceutical composition of claim 29, wherein the compound is present in an amount effective to inhibit inflammatory cytokine pathway.

31. (Previously Presented) The pharmaceutical composition of claim 29, wherein the compound is present in an amount effective to inhibit cell proliferation.

32. (Previously Presented) The pharmaceutical composition of claim 29, wherein the compound is present in an amount effective to exhibit an anti-inflammatory effect.

33-59. (Canceled)

60. (currently amended) A method for treating an inflammatory or autoimmune disorder or proliferative disorder comprising:

administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1 and in a pharmaceutically acceptable carrier or diluent; and optionally further comprising administering an additional therapeutic agent.

61-87. (Canceled)

88. (Original) The method of claim 60, wherein the inflammatory or autoimmune disorder or proliferative disorder is rheumatoid arthritis, ulcerative colitis/Crohn's disease, central nervous system diseases (CNS) such as multiple sclerosis, systemic lupus erythematosus, asthma, allograft rejection/graft versus host disease (GVHD), psoriasis, atopic dermatitis, eczema, urticaria, allergic rhinitis, myasthenia gravis, diabetes, idiopathic thrombocytopenia purpura, glomerulonephritis, cardiovascular disease, or cancer.

89. (Original) The method of claim 60, wherein the inflammatory disorder is rheumatoid arthritis.

90. (Original) The method of claim 60, wherein the inflammatory disorder is ulcerative colitis/Crohn's disease.

91. (Original) The method of claim 60, wherein the inflammatory disorder is multiple sclerosis.

92. (Original) The method of claim 60, wherein the inflammatory disorder is asthma.

93. (Original) The method of claim 60, wherein the inflammatory disorder is psoriasis.

94. (Original) The method of claim 60, wherein the inflammatory disorder is allograft rejection/GVHD.

95. (Original) The method of claim 60, wherein the inflammatory disorder is idiopathic thrombocytopenia purpura.

96. (Original) The method of claim 60, wherein the inflammatory disorder is allergic rhinitis.


97. (Original) The method of claim 60, wherein the inflammatory disorder is atopic dermatitis.

98. (Original) The method of claim 60, wherein the inflammatory disorder is systemic lupus erythematosus.

99. (Original) The method of claim 60, wherein the inflammatory disorder is glomerulonephritis.

100. (Original) The method of claim 60, wherein the inflammatory disorder is diabetes.








101. (New) The compound of claim 1, wherein said compound has the structure:















or a pharmaceutically acceptable salt thereof.








102. (New) The compound of claim 1, wherein said compound is selected from the group consisting of:

	ER-#	Structure
--	------	-----------










1	805600 (IC375)	
2	805894 (IC 400)	
3	806006	
4	805985 (IC403)	
5	805984	
6	806002	
7	805969	









8	805971	
9	805996	
10	805639 (IC 397)	
11	805895 (IC 405)	
12	806007	
13	805976	










14	805975	
15	805999	
16	806011	
17	805970	
18	805972	
19	805997	









20	806010	
21	806014	
22	806094	
23	806095	
26	806123	
27	806136	
28	806181	


















29	806221	
30	806220	
31	806224	
32	806228	
33	806276	
34	806275	
35	806274	
36	806273	
37	806286	









38	806287	
39	806311	
40	806317	
41	806320	
42	806329	
43	806333	
45	806336	
46	806355	









47	806358	
48	806359	
49	806363	
50	806362	
51	806361	
52	806368	
53	806372	
54	806373	
55	806374	

56	806375	
57	806383	
58	806393	
59	806401	
60	806402	
61	806404	
62	806417	
63	806419	










64	806420	
65	806421	
66	806432	
67	806435	
68	806437	
69	806569	
70	806609	
71	806610	

72	806644	
73	806645	
74	806646	
75	806647	
76	806653	
77	806671	
78	806781	










79	806790	
80	806796	
81	806820	
82	806839	
83	806840	
84	806841	
85	806842	
86	806843	









87	806844	
88	806860	
89	806874	
90	806875	
91	806878	
92	806899	
93	806900	
94	806901	




















95	806902	
96	806903	
97	806904	
98	806905	
99	806987	
100	807014	
101	807015	
102	807139	
103	807140	









104	807183	
105	807240	
106	807313	
107	807377	
108	807392	
109	807400	
110	807401	 Trans racemic
111	807399	 Cis racemic









112	807447	
113	807448	
114	807449	
115	807450	
116	807451	
117	807452	
118	807453	
119	807454	
120	807457	

121	807458	
122	807459	
123	807460	
124	807462	
125	807463	
126	807464	
127	807465	
128	807466	









129	807467	
130	807469	
131	807496	
132	807497	
133	807498	
134	807505	
135	807506	
136	807528	
137	807531	









138	807532	
139	807543	
140	807544	
141	807546	
142	807548	
143	807549	
144	807550	
145	807562	









146	807571	
147	807573	
148	807584	
149	807585	
150	807586	
151	807587	
152	807636	
153	807649	









154	807660	
155	807662	
156	807663	
157	807703	
158	807704	
159	807748	
160	807749	
161	807750	



















162	807751	
163	807754	
164	807758	
165	807759	
166	807762	
167	807779	
168	807787	
169	807788	

170	807789	
171	807790	
172	807794	
173	807835	
174	807836	
175	807837	
176	807862	
177	807865	










178	807876	
179	807892	
180	807920	
181	807930	
182	807931	
183	807952	
184	807956	
185	807962	

186	807976	
187	807977	
188	807978	
189	807980	
190	808009	
191	808028	
192	808036	
193	808039	










194	808040	
195	808041	
196	808069	
197	808078	
198	808079	
199	808080	
200	808081	
201	808082	







202	808083	
203	808084	
204	808085	
205	808086	
206	808101	
207	808102	
208	808103	
209	808107	










210	808128	
211	808151	
212	808152	
213	808153	
214	808160	
215	808164	
216	808247	
217	808254	

218	808255	
219	808256	
220	808257	
221	808259	
222	808260	
223	808261	
224	808262	
225	808266	
226	808268	





















227	808269	
228	808281	
229	808283	
230	808284	
231	808285	
232	808286	
233	808287	
234	808288	
235	808289	










236	808290	
237	808291	
238	808310	
239	808311	
240	808312	
241	808313	









242	808319	
243	808322	
244	808346	
245	808347	
246	808355	
247	808356	
248	808361	
249	808362	
250	808363	

251	808364	
252	808365	
253	808370	
254	808371	
255	808372	
256	808385	
257	808386	
258	808387	
259	808388	









260	808469	
261	808470	
262	808473	
263	808496	
264	808497	
265	808498	
266	808499	
267	808500	
268	808501	










269	808513	
270	808514	
271	808541	
272	808542	
273	808543	
274	808544	
275	808548	
276	808571	
277	808576	










278	808600	
278	808617	
279	808620	
280	808622	
281	808623	
282	808624	
283	808627	
284	808628	
285	808629	

286	808631	
287	808635	
288	808636	
289	808637	
290	808658	
291	808660	
292	808661	
293	808663	





















294	808665	
295	808672	
296	808673	
297	808675	
298	808691	
299	808692	
300	808702	
301	808703	










302	808704	
303	808705	
304	808711	
305	808712	
306	808713	
307	808714	
308	808717	
309	808719	
310	808720	











311	808833	
312	808834	
313	808835	
314	808836	
315	808849	
316	808983	
317	808984	
318	809047	
319	809187	

320	809189	
321	809190	
322	809191	
323	809192	
324	809193	
325	809196	
326	809197	
327	809198	
328	809199	









329	809200	
330	809201	
331	809202	
332	809203	
333	809204	
334	809205	
335	809206	
336	809207	








337	809208	
338	809209	
339	809210	
340	809211	
341	809212	
342	809213	
343	809214	
344	809215	
345	809216	
346	809217	

347	809218	
348	809219	
349	809220	
350	809221	
351	809222	
352	809223	
353	809224	
354	809225	
355	809226	

356	809227	
357	809228	
358	809229	
359	809230	
360	809231	
361	809232	
362	809233	
363	809234	
364	809235	
365	809236	




366	809237	
367	809238	
368	809251	
369	809252	
370	<u>IC261</u>	
371	IC375	
373	IC395	
374	IC396	
375	IC400	

		
376	<u>IC401</u>	
377	<u>IC402</u>	
378	<u>IC403</u>	
379	<u>IC404</u>	
380	<u>IC415</u>	
381	<u>IC416</u>	


or a pharmaceutically acceptable salt thereof .

103. (New) A compound having the structure:




or a pharmaceutically acceptable salt thereof.

104. (New) A compound having the structure of Formula II




wherein R<sub>1</sub> is OH or O-TBS (t-butyldimethylsilyl ether).

105. (New) A method of Claim 60, wherein said compound has the structure:



or a pharmaceutically acceptable salt thereof.

106. (New) A compound having the structure of Formula II



wherein:

n is 1 and R<sub>1</sub> is Cl; or

n is 0 and R<sub>1</sub> is -COOH.

107. (New) A compound having the structure:

